Another adalimumab biosimilar looks set to join the ranks in Europe, after the committee for human medicinal products (CHMP) within the European Medicines Agency (EMA) issued Fresenius Kabi with a positive opinion for its MSB11022 version under the names Idacio and Kromeya, one of which carves out a hidradenitis suppurativa indication.
Fresenius Nod In EU Adds To Crowded Adalimumab Market
Fresenius Kabi has become the latest firm to receive a nod for a European biosimilar rival to Humira, adding to an already crowded biosimilar adalimumab market.
